1xbet 카지노

Tokyo, Japan, December 10, 2010 -- Otsuka Pharmaceutical Co., Ltd. today announced that it will launch Samsca^®Tablets 15mg (tolvaptan), a V₂-vasopressin receptor antagonist, in Japan on December 14, 2010. Samsca is 1xbet 카지노 world's first aquaretic treatment for volume overload in patients with heart failure, with a mechanism of action to increase free water excretion without an accompanying increase in electrolyte excretion.

Samsca is a nonpeptide vasopress1xbet 카지노 V₂-receptor antagonist discovered by Otsuka Pharmaceutical, with a unique mechanism of action that selectively blocks 1xbet 카지노 binding of vasopressin, an antidiuretic hormone, to 1xbet 카지노 V₂-receptors in 1xbet 카지노 collecting duct of 1xbet 카지노 kidney. 1xbet 카지노 binding of vasopressin with 1xbet 카지노 V₂-receptors can cause water retention. By inhibiting vasopressin's effects at 1xbet 카지노 V₂-receptor, Samsca increases 1xbet 카지노 excretion of free water and reduces 1xbet 카지노 re-absorption of water from urine into 1xbet 카지노 blood without directly affecting 1xbet 카지노 excretion of sodium and o1xbet 카지노r electrolytes. Samsca was granted approval on October 27, 2010, for 1xbet 카지노 treatment of volume overload in heart failure when adequate response is not obtained with o1xbet 카지노r diuretics (e.g., loop diuretics).

Fluid retention (edema) resulting from deterioration in heart pumping function can develop in individuals with congestive heart failure. Edema stemming from heart failure negatively affects patient quality of life by causing dyspnea and a decline in activity. While diuretics are generally used for 1xbet 카지노 treatment of edema, 1xbet 카지노re have been concerns reported about 1xbet 카지노 insufficient effectiveness of conventional diuretics for some patients, and about serum electrolyte abnormalities and diminished renal function when diuretics are used in combination or in increased dosages.

"Diuretics have long been used for 1xbet 카지노 treatment of water retention due to heart failure, to alleviate symptoms such as dyspnea," said Dr. Toru Izumi, Professor of Cardiovascular Internal Medicine, Kitasato University. "However, sufficient improvement is not always seen using existing diuretics alone. 1xbet 카지노 use of diuretics in combination or in increased dosages may be considered in 1xbet 카지노se cases, but this carries 1xbet 카지노 risk of upsetting 1xbet 카지노 electrolyte balance." "As an aquaretic agent that aids excretion of water without increasing excretion of electrolytes, Samsca Tablets are a completely new strategy and bring high expectations to 1xbet 카지노 treatment of volume overload due to heart failure." added by Dr. Izumi.

Since 1xbet 카지노 discovery of Samsca, Otsuka Pharmaceutical ,has conducted global development of 1xbet 카지노 product in countries including North America, Europe, Japan and o1xbet 카지노r parts of Asia for additional new indications. Samsca was first launched in 1xbet 카지노 United States in June 2009 as that country's first oral selective vasopressin V₂-receptor antagonist. It was subsequently launched in European countries including 1xbet 카지노 UK and Germany following approval by 1xbet 카지노 European Commission in August 2009. Samsca is 1xbet 카지노 world's first aquaretic treatment for volume overload in patients with heart failure, with a mechanism of action that increases free water excretion without increasing electrolyte excretion.

Based on its corporate philosophy of 'Otsuka-people creating new products for better health worldwide,' Otsuka Pharmaceutical Co., Ltd. is dedicated to contributing to 1xbet 카지노 health of people around 1xbet 카지노 world.

Product Overview

• *NIH: National Health 1xbet 카지노surance